
IndraLab
Statements
KCNH2 inhibits potassium(1+). 25 / 25
|
24
1
reach
"The most frequently observed forms of congenital LQTS arise from mutations to KCNQ1 and hERG (alternative nomenclature KCNH2), which respectively contribute to the slow delayed rectifier potassium current (I , LQT1) and the rapid delayed rectifier potassium current (I , LQT2); these account for 44% and 35% of cases, respectively [9]."
reach
"A half-maximal inhibiting concentration (IC value) for the effect of Aspidasept on the hERG-mediated potassium current could not be calculated, because no significant effect on the hERG channel current at the highest concentration successfully tested (10 µg/mL) could be observed (Figure 8)."
reach
"In vitro studies found that supratherapeutic circulating concentration of loperamide is an effective inhibitor of both NaV1.5 and potassium human ether-a-go-go related gene (hERG) cardiac ion channels, with consequences on ventricular arrhythmogenesis and function.We recently performed an analysis of the World Health Organization pharmacovigilance database (VigiBase), encompassing more than 22 million reports from more than 130 countries."
reach
"Ng and colleagues at the Cardiological Society of Australia and New Zealand (CSANZ) annual meeting presented their data on IC-105574, a hERG channel activator which was shown to attenuate inactivation of the potassium (K) channel in Chinese hamster ovarian cell lines with inactivator mutations [2]."
reach
"Pharmacokinetic properties, druglikeness as well as other significant descriptors, such as molecular weight, H-bond donors, H-bond acceptors, solvent accessible surface area, log HERG (blockage of K+ channels), log S (aqueous solubility), log P (octanol and water), and human oral absorption, for the selected hits were determined by QikProp (XREF_TABLE)."
reach
"Class III (HERG channel-mediated rapid potassium current blockers) D, L-sotalol is generally avoided in frail patients with multiple comorbidities, polypharmacy, and frequent electrolytes disorders, but may be used in selected patients, more commonly for ventricular arrhythmias, if certain provision is followed such as QT interval monitoring and ensuing there is no significant left ventricular hypertrophy."
reach
"Computer calculations were performed using pharmacokinetic and pharmacodynamic data, including affinity to block the rapid component of the delayed rectifier cardiac potassium current (I Kr) encoded by the human ether-a-go-go gene (hERG), propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP)."